Contraception
Volume 82, Issue 2 , Pages 147-154 , August 2010

Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels

Received 1 July 2009 ,Revised 9 February 2010 ,Accepted 18 February 2010.

References 

  1. Alexander GM, Sherwin BB. Sex steroids, sexual behavior and selection attention for erotic stimuli in women using oral contraceptives. Psychoneuroendocrinology. 1993;18:91–102
  2. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2009;
  3. Stuckey BG. Female sexual function and dysfunction in the reproductive years: the influence of endogenous and exogenous sex hormones. J Sex Med. 2008;5:2282–2290
  4. Guida M, Di Spiezio Sardo A, Bramante S, et al. Effects of two types of hormonal contraception — oral versus intravaginal — on the sexual life of women and their partners. Hum Reprod. 2005;20:1100–1106
  5. Skrzypulec V, Drosdzol A. Evaluation of the quality of life and sexual functioning of women using a 30-microg ethinyloestradiol and 3-mg drospirenone combined oral contraceptive. Eur J Contracept Reprod Health Care. 2008;13:49–57
  6. Graham CA, Bancroft J, Doll HA, Greco T, Tanner A. Does oral contraceptive-induced reduction in free testosterone adversely affect the sexuality or mood of women?. Psychoneuroendocrinology. 2007;32:246–255
  7. Greco T, Graham CA, Bancroft J, Tanner A, Doll HA. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception. 2007;76:8–17
  8. Li RH, Lo SS, Teh DK, et al. Impact of common contraceptive methods on quality of life and sexual function in Hong Kong Chinese women. Contraception. 2004;70:474–482
  9. Witting K, Santtila P, Jern P, et al. Evaluation of the female sexual function index in a population based sample from Finland. Arch Sex Behav. 2008;37:912–924
  10. Caruso S, Agnello C, Intelisano G, et al. Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol/60 microg gestodene. Contraception. 2004;69:237–240
  11. Park K, Ahn K, Lee S. Decreased circulating levels of estrogen alter vaginal and clitorial blood flow and structure in the rabbit. Int J Impot Res. 2001;13:116–124
  12. Berman JR, Goldstein I. Female sexual dysfunction. Urol Clin North Am. 2001;28:405–416
  13. World Health Organization . Medical Eligibility Criteria for Contraceptive Use. 2008 Update. Geneva: World Health Organization; 2008;Available at: http://www.who.int/reproductive-health/publications
  14. Rosen R, Brown C, Heiman J, et al. The female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191–208
  15. Hentschel H, Alberton DL, Capp E, Goldim JR, Passos EP. Validação do Female Sexual Function Index (FSFI) para uso em língua portuguesa. Rev HCPA. 2007;27:10–14
  16. Shifren L, Davis S, Dennerstein L, Heiman J, Lobo R, Simon J. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause. 2005;12:497–511
  17. Dupont WD, Plummer WD. Power and sample size calculations for studies involving linear regression. Control Clin Trials. 1998;19:589–601
  18. Darney PD. The androgenicity of progestins. Am J Med. 1995;98(1A):104S–110S
  19. Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab. 2006;91:3697–3710
  20. Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001;64:51–58
  21. Graham CA, Ramos R, Bancroft J, et al. The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception. 1995;52:363–369
  22. Lete I, Doval JL, Pérez-Campos E, et al. Self-described impact of noncompliance among users of a combined hormonal contraceptive method. Contraception. 2008;77:276–282
  23. Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007;76:267–272
  24. Torréns JI, Sutton-Tyrrell K, Zhao X, et al. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women's Health Across the Nation. Menopause. 2009;16:257–264
  25. Leão LM, Duarte MP, Silva DM, et al. Influence of methyltestosterone postmenopausal therapy on plasma lipids, inflammatory factors, glucose metabolism and visceral fat: a randomized study. Eur J Endocrinol. 2006;154:131–139
  26. Sowers MF, Zheng H, McConnell D, et al. Testosterone, sex hormone-binding globulin and free androgen index among adult women: chronological and ovarian aging. Hum Reprod. 2009;24:2276–2285
  27. Cho LW, Kilpatrick ES, Jayagopal V, Diver MJ, Atkin SL. Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia. Clin Endocrinol (Oxf). 2008;68:390–394
  28. Winkler UH, Sudik R. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception. 2009;79:15–23
  29. Palombo-Kinne E, Schellschmidt I, Schumacher U, Gräser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception. 2009;79:282–289
  30. Mueller A, Dittrich R, Cupisti S, et al. Is it necessary to measure free testosterone to assess hyperandrogenemia in women? The role of calculated free and bioavailable testosterone. Exp Clin Endocrinol Diabetes. 2006;114:182–187

PII: S0010-7824(10)00060-0

doi: 10.1016/j.contraception.2010.02.016

Contraception
Volume 82, Issue 2 , Pages 147-154 , August 2010

Article Tools

* Image Usage & Resolution